Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML-Reference-Cited by-同舟云学术

Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

Published:2018-06-21 Issue:25 Volume:378 Page:2386-2398
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

DiNardo Courtney D.¹,Stein Eytan M.¹,de Botton Stéphane¹,Roboz Gail J.¹,Altman Jessica K.¹,Mims Alice S.¹,Swords Ronan¹,Collins Robert H.¹,Mannis Gabriel N.¹,Pollyea Daniel A.¹,Donnellan Will¹,Fathi Amir T.¹,Pigneux Arnaud¹,Erba Harry P.¹,Prince Gabrielle T.¹,Stein Anthony S.¹,Uy Geoffrey L.¹,Foran James M.¹,Traer Elie¹,Stuart Robert K.¹,Arellano Martha L.¹,Slack James L.¹,Sekeres Mikkael A.¹,Willekens Christophe¹,Choe Sung¹,Wang Hongfang¹,Zhang Vickie¹,Yen Katharine E.¹,Kapsalis Stephanie M.¹,Yang Hua¹,Dai David¹,Fan Bin¹,Goldwasser Meredith¹,Liu Hua¹,Agresta Sam¹,Wu Bin¹,Attar Eyal C.¹,Tallman Martin S.¹,Stone Richard M.¹,Kantarjian Hagop M.¹

Affiliation:

1. From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) — both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.);...

Funder

Agios Pharmaceuticals, Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1716984

Cited by 1056 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches;Cancers;2024-02-05

2. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation;Oncology and Therapy;2024-02-01

3. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

4. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

5. Generation of a new therapeutic d-peptide that induces the differentiation of acute myeloid leukemia cells through A TLR-2 signaling pathway;Cell Death Discovery;2024-01-26